Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 472 clinical trials
Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19

Study timepoints will include Day 1 screening/enrollment, 30 day, 60 day, and 90 day assessments. Questionnaires will be collected in all timepoints.

pediatric
hydroxychloroquine
SARS
acute respiratory syndrome (sars)
occupational exposure
  • 0 views
  • 19 Feb, 2024
4SCAR-T Therapy Post CD19-targeted Immunotherapy

This study will evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells (4SCAR-T) targeting CD19-negative B-ALL that express alternative surface antigens such as CD22, CD10, CD20, CD38, and CD123, as many patients relapse after anti-CD19 immunotherapy.

  • 0 views
  • 19 Feb, 2024
ADME Study of Acoziborole in Healthy Subjects

This is a single centre, open-label, single group, non-randomised, single oral dose study in healthy male subjects designed to assess the mass balance recovery, PK, metabolite profile and metabolite identification, and exploratory pharmacodynamics of acoziborole. It is planned to enrol 6 subjects. All subjects will receive an oral dose of …

  • 0 views
  • 19 Feb, 2024
A Study to Evaluate the Tolerance Efficacy and Pharmacokinetics of TQB3558 Tablets

This is a study to evaluate the maximum tolerated dose (MTD) , occurrence of all adverse events (AE) and serious adverse events (SAE) , pharmacokinetic parameters and antitumor effect of TQB3558 tablets in Chinese adult patients with advanced solid tumors .The study is divided into phase Ia and phase Ib.

  • 0 views
  • 19 Feb, 2024
Determinants of Neonatal Anemia in Women Carrying Multiples  

Determinants of neonatal anemia will be identified. Inflammatory markers will be measured in all blood samples and related to outcomes. Stable iron isotopes will be given to a subset of women to assess maternal Fe absorption and fetal Fe uptake.

Accepts healthy volunteers
  • 0 views
  • 22 Feb, 2024
  • 2 locations
Teaching Novel Values-Based Skills to Improve Long-Term Weight Loss

This NIDDK funded R01 project is a randomized controlled clinical trial to compare the efficacy of an intervention based on Acceptance and Commitment Therapy (ACT) and a Self-Regulation (SR) intervention on weight loss maintenance over a 30-month period. All participants will first complete a well-validated online weight loss intervention (months …

body mass index
acceptance and commitment therapy
  • 0 views
  • 19 Feb, 2024
Intratumoral Tilsotolimod a TLR-9 Agonist Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers

The trial will be divided into two parts: PART A: the first part will assess the safety of two regimen and will recruit patients with all types of injectable solid malignancies PART B: the second part will include 3 expansion cohorts of 15 patients: B1: anti-PD-1 refractory advanced NSCLC cohort …

cancer treatment
blood transfusion
cancer therapy
hcg pregnancy test
neutrophil count
  • 0 views
  • 19 Feb, 2024
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Since the study is "blinded," patients and their doctors will not know whether a patient gets brentuximab vedotin or placebo. All patients in the study will get rituximab and lenalidomide. These are drugs that can be used to treat DLBCL.

lenalidomide
ct scan
lymphoma
rituximab
avid
  • 0 views
  • 19 Feb, 2024
Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) Before and During Treatment With Ocrelizumab

This is an open-label, multicenter study that includes a main study for all participants enrolled and an optional cerebrospinal fluid (CSF) sub-study. Self-identified African American (AA) and Hispanic or Latin American (HA) participants with a diagnosis of relapsing multiple sclerosis (RMS) will be enrolled.

  • 0 views
  • 19 Feb, 2024
89Zr-atezolizumab PET Scan and Lobular Breast Cancer

Ten patients with lobular metastatic breast cancer, who are included in the GELATO trial at the UMCG, are eligible for the ImaGelato study. All patients will undergo two Zirconium-89 (89Zr)-atezolizumab positron emission tomography (PET) scans, one at baseline and one after two doses carboplatin induction treatment.

  • 0 views
  • 19 Feb, 2024